ABSTRACT
Bad<ground and introduction
The USEPA (EPA)i has established the use of relative potency approaches, i.e., toxic equivalent (TEQ)-Iike approaches, for mixtures risk assessment. TEQ-Iike approaches assume that if the following four key pharmacological or toxicological premises are met, (1) chemicals are true congeners, (2) are metabolized and detoxified by the same biological processes, (3) produce the same spectrum of biological effects by the same mode of action, and (4) exhibit parallel dose response curves for the biological effect being modeled (Safe, 1990) , then one may assume that in mixtures, those chemicals observable response range, whereas DA would predict an increased res ponse.
The main obstacle to applying DA broadly for diverse groups of chemicals has been the required demonstration that the underlying TEQ premises are met (Safe, 1998) . The latter has prompted argumentation that the TEQ concept is too restrictive for cumulative risk assessment. Indeed, the definition of DA does not include TEQ requirements, as DA is a purely quantitative model of combined action that does not require specific chemical, toxicological or pharmacologi cal properties and requires only that the underlying dose response relationship is quantified according to a common biological metric. However, TEQ premises (Table 1) have been included explicitly to increase the reliability of extrapolating the DA mod el to dose ranges, chemical ratios, and species that have not been tested empirically (Safe, 1998) . Hence, requiring similarity of mode of action and biological effects serves to reduce the potential for differences in the molecular, cellular and physiological response characteristics of different mixtures components from producing non-dose-additive combined action. Consequently, inclusion criteria (Tabl e 1) reduce the potential for pharmacokinetic differences to alter DA combined action expected at molecular, cellular and physiologic levels based on similar modes of action and toxic effects, and increase confidence in treating a mixture of chemicals as if it were the total equivalent dose of the prototype chemical alone. In contrast, chemicals with non-parallel dose response curves have different relative potencies at different doses and thus, cannot reliably be treated as simple dilutions of a prototype chemical across all doses and ratios (Fi g. 1) .
One prominent example of how rejecting TEQ premises may lead to misinterpretation of data and over-interpretation of risk is the report "Phthalates and Cumulative Risk Assessment: Tasks Ahead" by the National Research Council (NRC, 2008) . The report asserts that based on th e available data for phthalates and other chemicals that result in androgen deficiency by different modes of action (anti-androgens), cumulative risk assessment should be conducted by applying DA to all chemicals that produce "common adverse outcomes" (CAOS) rather than only to chemicals satisfying TEQ criteria. Further, the report recommends DA to the exclusion of other models of combined action, such as lA, irrespective of whether chemicals exhibit parallel dose response curves for CAOS, and places no other restrictions on th e application of DA to CAOS (DA-CAOS), including potency, ex posure level, or mechanistic assumptions regarding the anti-androgenic effects.
Some phthalates and other chemicals with potential antiandrogenic properties have been found to produce malformations of the developing male reproductive tract in rats, an observation to which some researchers have attached the collective name "phthalate syndrome" (Foster, 2005) . The mode of action for these Table 1 Chemical sim ilarity criteria for applying DA in cumulative (mixtures) risk assessments. Extrapolating DA requires parallel dose-response curves. In panel a. dose response cUlves for chemicals Y. Wand T are parallel and there is a consta nt proportionality between the curves, illustrated by the arrows. renecting the fact that the potency differences are constant at every response level. (Y-T; Y-W) thus give relative potency factors Z, and Z, for those chemicals, which e nable prediction of the dose-additive response for untested dose combinations by transforming any dose ofT or W to its equival ent dose of Y. DA Response IY.T.wl = Response IY + (T-Z,)+(W-Z,)]. These relationships hold for any number of chemicals with parallel dose response curves. In panel b. dose response curves for chemicals Y and T are not parallel. resulting in a different proportionality between the curves at every response level (dashed lines). renecting a different relative potency Y-T at every response level. Thus, there is no uniform function that will accurately transform T into an equ ivalent dose of Y. and so predicting DA Response [Y.T] becomes highly uncertain for doses not tested empirically. Uncertainties expand with increasing numbers of chem icals with non-parall el dose response character.
effects is believed to involve an impairment of fetal Leydig and Sertoli cell function, leading to androgen deficiency in the developing reproductive tract of male rats (David, 2006) . Similar malformations have been reported in other species, however species differences in response to phthalates are apparent (Gaida et al., 2007; Johnso n et aI., 201 1; Lambrot et aI., 2009; Hallmark et al., 2007) . Based on certain similarities between these malformations in rodents and a so-called testicular dysgenesis syndrome (TDS) in humans (Skakkebaek et aI., 2001) , some have speculated that TDS may be caused by exposure to anti-androge nic chemicals (Skakkeba ek et aI., 2001; Foster, 2005) .
Mixtures studies (Table 2) conducted by two research groups, one based at universities in Europe (Christiansen et aI., 2008 (Christiansen et aI., , 2009 Hass et aI., 2007; Metzdorff et aI., 2007) and the other at EPA (Hotchki ss et aI., 2004; Howdeshell et aI., 2007 Howdeshell et aI., , 2008 Rid er et aI., 2008) have reported DA combined effects on the developing mal e reproductive tract of rats for anti-androgens that differ in molecular structure as well as in their mechanism of action and pattern of anti-androgenic effects, Based on those findings, it has been reaso ned that limiting the application of DA only to chemicals that fit TEQ criteria may be insufficiently inclusive and thus, Organ system (CADS) Target organ Molecular target Cellular target Toxic intermediates Phannacokinetics Detoxification pathways Parallel dose-res ponse curves Chem ica l structure Table 2 Mi xture studies of anti-and rogens in rats. produce insufficiently conservative human healt h risk assessments that fail to protect from TDS (NRC, 2008 ) . Subseq uently. two human health risk assessments have been co nduc ted usin g NRC's ass umpt ions, both of which employed a haza rd index calculation to estim ate ri sks (Tab le 2). One considered exposure to a mi xtu re of six phthalate esters (Benson, 2009 ) , whil e the other utilized the full DA-CAOS concept, considering exposure to a mi xture of 15 potential ant i-androgens spanning a range of chem ical stru ctures and mod es of action including phthalate es ters, pesti cides, and industria l chemi ca ls (f(orte nkamp and Faust, 20 10).
Study

Analysis of mixtures studies, rislc assessment of antiandrogens, and predictions of DA-CAOS
The DA-CAOS conce pt obviously co nt rave nes well-established pharmacologica l prin cipl es for definin g relative potency of adverse outcomes. In vi ew of thi s, an in -depth analysis of the e mpirica l and theoretical foundations of th e DA-CAOS co nce pt and the res pective Co ncluded that 95% UCI exceeds acceptable ri sk levels practical consequences of its use w as carried out. As well, potency assumptio ns made in risk assess ments based on the DA-CAOS concept were evaluated. The followin g analyses were conducted : (i) An evaluation of th e extent to which the study designs employed to test mixtures (Table 2) can su pport the extrapolation of DA versus IA to lower, untested doses and chemical rati os. (i i) A statistical ana lysis of variability within the published data for one endpoint evaluated in the mi xtures studies as an exa mple to illustrate the uncertainty that might evolve from extrapolation of the DA-CAOS assumption to lower, untes ted doses and chem ica l ratios. (iii ) A co nsid eration of wheth er the DA-CAOS concept can be reconciled with the pharmacologica l basis und erlying relat ive potency approaches. (iv) an evaluation of th e logical extensions of the DA-CAOS co ncept and resulting risk as sessm ent for co nsistency with human clinical and epidemiologica l observation s, and:
(v) A comparison of humans versus rat sensitivity to chemicals with anti-androgenic properties to test the premise and key default assumption of the risk assessment based on DA-CAOS ((ortenkamp and Faust, 2010) , that the developing male reproductive tract of humans responds to chemicals at doses two orders of magnitude lower than those required to affect rats.
As shown below, these five analyses demonstrated that the DA-CAOS concept and the risk assessments conducted per its premises are scientifically untenable. Consequently, an alternative approach -the Human-Relevant Potency-Threshold (HRPT) approach -was developed to better fit the data and to avoid the contradictions that arise in using the DA-CAOS concept.
Study designs
Five criteria for evaluating interaction studies used in risk assessment have been defined (Borgert et aI., 2001) and were used to assess the mixtures studies listed in Table 2 . Criterion 1 addresses the fact that the better defined the dose response parameters for the individual chemicals, the more reliably distinctions can be drawn between different combined effect models. Criterion 2 requires that non-interaction model(s) be explicitly defined since inferences of greater-than-additive (synergy) or less-than-additive (antagonism) are typically made 'on the basis of statistically significant departures from a defined non-interaction model? Usually, DA and lA are the competing models of non-interaction tested. Criterion 3 requires testing an adequate number of combinations across a sufficient dose range to meet the goals of the study. The latter is important as combination effects can vary with the concentrations and with the ratios of mixture constituents. Criterion 4 requires formal statistical tests to distinguish the combined response from the response predicted by the non-interaction model. Prerequisite for a robust statistical analysis is to account for biological variation and experimental error. Finally, Criterion 5 requires the evaluation of interactions at a relevant level(s) of biological organization. Combination effects measured at molecular, cellular and higher-order physiological endpoints may be necessary to gain an unambiguous understanding of the biological response to a mixture.
Study ciesigns: Dose ranges and ratios
Conducting experiments in whole animals or human subjects often prevents satisfying all five criteria (Price et aI., 2002; Borgert et aI., 2001) due to the difficulty of obtaining sufficient dose-response information. Those limitations affect the studies under consideration here (Table 2) , as acknowledged by some of the authors (e.g., Hass et aI., 2007) . Nonetheless, greater co nformity with the five criteria provides for more unequivocal data interpretation across the concentration ranges tested. In contrast, studies fulfilling fewer criteria or with less stringency must be interpreted with more caution, i.e., limiting the interpretation to the specific dos es and ratios tes ted . Uncertainties are compounded when combination effects are extrapolated to doses and ratios not tested empirically.
The interpretations supportable from a mixture study are inherently dependent on the quality of dos e-respons e data available for the individual mixture components, which should be tested across a co ncentration range and with a sufficient number and spacin g of doses to reveal maxima, minima, points of inflection, and regions of linearity (Borgert et aI., 200 1) . The mixtures studi es (Tabl e 2) used for the risk assessment of anti-androgens ((ortenkamp and Faust, 2010) varied widely in their characterization of dose response data for the individual chemicals. In some studies, as many as seven doses were tested while in other studies, dose response data from prior experiments and different rat strai IlS were used as surrogates. In most instances, dose response mod e ls w ere used to curve-fit the data, and model parameters obtained from single chemical experiments were used to predict mixture effects.
All of the studies employed single ratios of chemicals to simulate mixture effects (Tab le 2). This design is often referred to as a fixed ray design (Cassee et aI. , 1998) and has advantages over experimental designs employing only a single concentration of the mixture components because it allows local interpretations beyond one data point. A fixed ray design may be the broadest study design achievable in live animals due to limitations on the manageable size and number of dose groups (Cassee et aI., 1998 ; Pri ce et aI., 2002 ) , but this feature should constrain the interpretations to the ratios tested and preclude extrapolation to untested ratios. Several of the studies chose individual constituent ratios predicted to yield an equal contribution from each component across the entire range tested, however, confidence in that prediction is unjustified unless all components have parallel dose response characteristics. It is highly questionable whether the slopes of the dose response data for male reproductive tract effects of the individual chemicals are sufficiently similar to support this assumption. Although DA assumptions and calculations can be made for chemicals with non-parallel dose response curves, the reliability of those calculations diminishes rapidly as they are extrapolated beyond the ratios and concentrations tested empirically (Fi g. 1) (Cassee et aI. , 1998; Borgert et aI., 2001 ; Price et aI.,
2002).
Although the mixtures studies (Table 2 ) all reported testing "low doses" of the mixture components administered to dams, this term must be understood in the context of the phYSiological system. The doses tested appear to be within an order of magnitude of the observable response range for physiologically relevant anti-androgenic effects. For example, Rider et al. (2008) reported that the mixture doses used in their study were below the observable response range for malformations of the developing male reproductive tract in rats, i.e., procymidone at a maternal dose of 7.5 mg/kg/day. Contrary to the latter no observable effect assumption, Metzdorff et al. (2007) reported that 5 mg/kg/day procymidone produced statistically significant changes in seminal vesicl e weight, and 10 mg/kg/day produced changes in testis, ventral prostate, levator ani/bulbocavernosus muscle, and bulbourethral gland weights, thus suggesting that Rider et al. (2009) were testing mixtures containing doses of procymidone well within the observable effect ran ge for anti-androgenic action .. Further, although Rider et al. (2008) reported that vinclozolin was without statistically significant effects at 3.75 mg/kg/day, Metzdorff et al. (2007) reported that a slightly higher dose of 10 mg/kg/day vinclozolin produced statistically significant changes in epididymal, ventral prostate, and seminal vesicle w eights. These examples demonstrate the substantial variability that exists in defining the observabl e res ponse range, especially for endocrine-sensitive endpoints (Ashby, 2003) . Because the comparison of no-interaction dose-response models for mi xtures, i.e., DA versus lA, entirely depends on the precision of the no observable effect estimate, this latter precision must influence the confidence placed on the interpretations drawn from such data, as exemplified below. Rider et al. (2008) also showed that individual phthalates (dibutyl phthalate and diethylhexyl phthalate) failed to increase the incidence of male reproductive tract malformations at maternal doses below 500 mg/kg/day,3 but that in a mixture with the anti-androgenic pesticides vinclozo!in, procymidone, prochloraz, and !inuron, doses of 75 mgjkgjday of butyl benzyl phthalate, dibutyl phthalate and diethylhexyl phthalate contributed to an increased incidence of observable ma lformations.
4 This suggests that the combination of the three phthalates (75 mgjkgjday each, thus a total of 220 mgjkgjday) would provide for an effect greater than the no observable effect estimate demonstrated for 500 mgjkgjday of dibutyl phthalate or diethylhexyl phthalate. In a previous study by the same group, these three phthalates reduced fetal testosterone production at doses of 300 mgjkgjday individually and at doses of 60 mgjkgjday in combination with two other phthalates (Howdeshell et aI., 2008b) , suggesting that the three phthalates alone (butyl benzyl phthalate, dibutyl phthalate and diethylhexyl phthalate) would reduce fetal testosterone production when combined in a mixture at approximately 100 mgjkgjday each. Thus, although the doses of phthalates and other chemicals used in these mixtures were statistica lly below their individual no effect levels on male reproductive tract malformations in particu lar studies, they are nonetheless close to the dose range that produces a clear reduction in fetal testosterone individually and in mixtures. Slight differences in the experimental protocols, time of dosi ng, or rat strain could explain these differential responses. Regardless of the underlying reason, this comparison underscores how imprecise the distinctions might be regarding the no observable effect level for androgen sensitive tissues, and ill ustrates that the label "low dose" cannot be taken to mean a dose that is without a physiologically relevant anti-androgenic effect. To put the doses used in these rat studies into perspective with human-relevant exposures, the "high intake" level of vinclozo!in and procymidone (9 ~gjkgjday) and butyl benzyl phthalate (4 ~gjkgj day), dibutyl phthalate (6 ~Lgjkgjday), and diethylehexyl phthalate (3.6 ~gjkgjday) estimated for the US population are roughly 3-4 orders of magnitude lower (Kortenkamp and Faust, 2010) .
Despite limitations just described, the DA-CAOS concept was extended well below the dose range where DA was demonstra ted (Korte nkamp and Faust, 2010 ; NRC, 2008 ) . Fig. 2a il lustrates the general study designs that have produced DA mixture effects from "no-effect" combinations of anti-androgeni c chemicals with different modes of action. Fig. 2b illustrates how the DA-CAOS approach extrapolates the same studies depicted in Fig. 2a to far lower doses of the mixture components, which w ere not tes ted empirica ll y. The conservatism introduced here goes w ell beyond extrapolating observed toxicity from high to low doses; that conservatism is compounded by the choice of DA over IA based on very li mited study designs.
1.Study design: Endpoints and dose response metrics
Mi xtures studi es on potenti al anti-androgenic chemicals consistently report conformity with the DA model of combined action, however, those studies report inconsistent results as to whether the data also conform to IA (Tab le 2 ). For exa mpl e, one study reported that IA under-predicted combination effects and only DAmodels adequately fit the data fo r all malformations combined (Rider et aI., 2008), whereas another study (Christiansen et aI., 2009 ) fo und that the data for most endpoints could be fit adequately by either model, with so me greater-than-additive exceptions. The inconsistency of results obtained from the different approaches used by these two research groups co uld be du e to any number of factors, including th e animals used, the exact doses tested, th e way endpoints were meas ured, or slight differences in the mathematica l algo rith ms used for DA and IA.
Alth ough the application of DA is not constrained to any particular type of effect, th e use of scored endpoints, which are inherently subj ective (Hasc hek et aI., 2010 ), presents chall enges for Log Dose
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Log Dose (Table 2 ) have been performed relative to the dose-response curves for obselvable e ffects (Q). Panel a: Gene ration of dose add iti on data. Avai lable data suggest that sub-effective doses of a few such che micals may produce a DA response when the dose of each is within S, i.e" near the observable response region Q. Panel b. Ex tra polat ion of mixture data to DA-CAOS model. Th e DA-CAOS concept assumes that doses of such chemica ls far below the observable response region (S) also operate by DA and may produce an obselvable response if su fficient numbers of chemi cals are present. However, no data support this extrapolati on (P).
analyzing ex perimental variance not typically enco untered when continuous variables are measured according to objective scales. Several of the mixtures studies listed in Table 2 assessed scored endpoints, but it is uncl ear how variance was assessed statistically for these endpoints, if it was addressed at all. Except for gubernacular underdevelopment (not ca tegorized as a malformation above a certain length), all other male reproductive tract malformations were combined into a single group, further complicating the assessment of experimental variance; it is unclear if or how this was addressed in the statistical analysis (H owdeshell et aI., 2007; Rider et aI., 2008) . Other studies categorized fetal malformations accord ing to a four-point scale that included none observable, mild, moderate, or severe (Christiansen et aI., 2008 (Christiansen et aI., , 2009 ). To reduce those scores to a dichotomous variable suitable for statistical analysis used to tes t DA versus IA combined effect models, moderate and severe ma lformations were grouped toge ther in the "malformations" category, while mi ld malformations were grouped toge ther with no observable malform ations in the "no-effec t' category. Although this practice all ows some statisti cal analysis of results, it introduces additional potential errors of interpretation. IA predicts that no-effect doses of individual chemicals will also produce no effect when combined. Therefore, including mild malformation s or gubern acular und erdevelopment in the no-effect category for si ngl e chemical res ponses, as was done in some analyses (Christiansen et aI., 2008 (Christiansen et aI., , 2009 ) increases the chance that malformations will be observed when so-call ed "no-effect" doses of several chemicals are combined in the mi xtures study. Beca use malformation severity also increases with dose, th ese methods of scoring and grouping malformations may have ensured rejection of the lA model or biased the analysis toward synergism because a slight increase in "dose" from the combination of agents would raise certain mild malformations to the moderate/severe category. The uncertainty introduced by this procedure was not addressed, and methods for assessing its impact are lacking. The fact that small differences in experimental protocol or analysis alter the results of the mixture experiment raises concerns as to the degree of uncertainty inherent in interpreting the results for risk assessment. The risk assessment of anti-androgens chose DA over lA based on a stated preference for the more conservative model (I<o rte nka mp and Faust, 2010), however, the implications of inconsistent results for extrapolating to untested doses and mixture ratios appear to have been overlooked.
Statistical analysis of variability
In order to provide an objective estimate of the potential uncertainty contributed by the dose response information discussed above, data presented in one of the published mixture studies (Rider et aI., 2008 ) was evaluated. Because the original raw data were unavailable, data points were inferred from published figures (Rider et a!., 2008, Fig. 1) . In order to be as consistent as possi ble with the published study, the dose response model used to fit the published data (Rider et a!., 2008) was also used in the analysis presented here, Specifically, based on the data points inferred from the graphs published by Rider et a!. (2008) and the dose response model they fit to their data, a dose-response curve was developed and then data points were generated from the theoretical curve. A number of different samples were obtained in this way. Such iterations of the dose-response experiment comprise a statistical bootstrap procedure (Efron and Tibshirani. 1993) , and the results are presented in a series of isobolograms (Fig. 3) . The variability in the bootstrap samples is representative of that in the original data, providing a clear picture of the range of doses consistent with any particular level of response.
Isobolograms are a simple means of graphically evaluating data on binary mixtures for conformity to DA. Doses of one of the mixture components are plotted alon g the abscissa and the other along the ordinate. The equation for DA describes a line connecting equally effective doses of these two chemicals on the ordinate and abscissa. All other equally effective doses, representing defined mixtures of both components, are DA if they fall on the line, less than DA if they fall above the line, and greater than DA if below the line. Since some degree of variability and experimental error are inherent to the measurement of any observation or biological endpoint, the lines of additivity representing DA combination doses in an isobologram must be enveloped by statistical The left panel is an isobologram for two agents. Dose 1 and Dose 2, at 50% response. Dose addition (DA) defines a line connecting eq ually effective doses of Dose I and Dose 2 ad mini stered individually. Points above the line would demonstrate less-tha nadditive (antagonistic) dose com binations, below the line, greater-than-additive (synergistic). The dose is plotted on a log 2 sca le. so a change from 2 to 4 on the log 2 sca le wou ld represent a doubling of the dose. The center panel shows a coll ection of isoboles at differe nt response levels. Aga in , each line represents a co nsta nt response over the mixture of doses. The ri ght panel shows the output from one ana lysis, a nd depicts all of the isobolograms. from 5% to 95% response. As this is the output from one sampl e, the isobolograms w ill va ry from sampl e to sa mpl e. 3-2: This varia tion is illustrated for the data inferred from Fig. 1 of Rid er e t ai. (2008) . The estimated variance in eq ui -effective doses, and thus, the extent of unce rtainty surrounding the DA prediction. is illustra ted by comparing how the 95% effective dose for one mixture component changes across experiments as plotted on the abscissa. The lowest log (base-2) dose estimated to produce a 95% res ponse is approximately 1.7 (panel e) whereas the hi ghest dose estimated to produce the same level of response is approximately log dose 3.2 (panel c). indicating that the iso-effecti ve dose of just one mixture component can vary nearly 2-fold even within the observed data. The parallel lin es correspond to isoboles for equi-effective doses at lower response levels indi cate that the variance at lower do ses and response levels is proportional to the variance at hi ghe r doses and response levels, i.e., nearly twofold. confidence intervals defined by this variance. Assays with higher variance and/or experimental error will produce larger confidence intervals than assays with lower variance and/or experimental error (Borge rt et a I. , 2005 ). The variability attending any DA prediction can be estimated by observing how the equi-effective dose of each mixture component varies from experiment to experiment. The isobolograms shown in Fi g. 3(2), a-f indicate considerable variance within the published data, despite th e fact that the bootstrap procedure used to generate the new "data" on which the isoboles in Fig. 3 (2) were constructed employed the underlying dose-response model that Rider et al. (2 008) concluded best fit their data. Even within these contrived, bes t-cas e experiments, nearly 2-fold variance is observed, indicating that this variability surrounds any DA conclusion, even within the range of doses tested empirically. It is thus surprising that Rider et a l. (2008) un equivocally excluded IA for nearly all of the reported combination effects, si nce this requires an abse nce of overlap between IA and DA predictions after accounting for the experimental variance. It is uncl ear how this variance was handled in the analysis of combination effects (Rid er et ai., 2008) . Similar to the analysis presented here, other studies employed a bootstrap procedure to assess vari ance, and on that basis, concluded that both IA and DA predi cted most of the mixture res ponses (M etzdorff et al., 2007 ) .
It is critical to appreciate that for assessing risk, the DA-CAOS theory extrapolates the DA model beyo nd the doses and ratios tested in mixtures studi es (I<ortenkamp and Fa ust, 2010) . Since the apparent variance of the data within the range of doses tested in those studi es (Tabl e 2 ) raises questions as to whether a siligle model of combined action ca n be unequivocally decla red the most accurate, even for all mixture ratios within that dose ran ge, extrapolation to much lower doses and different mixture ratios would be quite tenuous. Little attention was given to the fact that the uncertainty of the predictions will expand in accordance with the variance in the data, other than to justify the choice of t he model on a prefe ren ce for conservatism.
The statistical analysis presented here has implications for the feasibility of selecting a 'best' model of com bined action as well as for future mixtures studies aimed at supporting such a determination . Unless the observed variance were so small that no significant overlap of DA and IA model predictions could occur as the model is extrapolated across untested dose ranges, it would be futile to attempt to select a model of combined action based on a stati stical analysis of mixtures data within the obselved response region . Indeed, the research group from Europe found that DA and IA overlapped even within the dose regions tested (Table 2 ), substantiating thi s point.
Relative potency and pharmacokinetics: Pharmacological principles
In addition to the problems di scussed above, the DA-CAOS theory contravenes fundamental pharmacological principles of receptor/enzyme affinity, intrinsic activity, and potency. Affinity is a term referring to the strength of attachment between two molecules and is applicable to interactions of a small liga nd with a larger macromolecule such as an intracellular or membrane-bo und receptor, an ion channel, an enzyme, or speci fi c binding protein.
For si mplicity, all of these are referred to as 'receptors' with the understanding that th e ge neral principles apply to all such interactions with macromolecules. The affinity of a ligand for a specific receptor determin es its residence time of ass ociation, .a parameter often quantified by the di ssociation constant. Generally, higher affinity liga nd s have longer residence tim es. Intrinsic activity is the relative ability of a drug-receptor complex to produce a maximum functional res ponse and is sometimes used interchangea bly with effi cacy. However, 'intrinsic activity' refers to a cellular respo nse whereas 'efficacy' is more often used in the context of a clinical response. Ass uming equi va lent pharmacokinetic parameters and affi nity, a drug with greater intrinsic activity would have greater efficacy. Potency is th e intensity of effect produced per unit of dru g, and is a function of intrinsic activity and affinity.
Because most receptor-based physiological responses can be triggered when only a small fraction of avail able receptors are activated by a strong agoni st (a li ga nd with hig h affinity and intrinsi c activity), receptor ligand s w ith velY low affinity and no intrinsic activity (weak antagonists) will fai l to interfe re with endogenous agonists unl ess their concentrations reach levels that obstruct access to the receptor by shear mass action. The sa me principle applies to com petitive inhibitors of enzymes involved in steroidogeni c pathways or to activators or blockers of ion channels in cellular membranes. Thus, because of vastly different residence times, liga nd s with very low affi nity spend such little time in contact with a receptor that they produce no disce rnibl e interference with hi gh-affinity li ga nds unl ess th ei r concentrations reach a sufficient level that interference by mass action occurs. In other w ords, low affinity li ga nds cannot co mpete with hi gh affinity li ga nds by their strength of attac hment, but rath er, only by shear numbers of mol ec ules that impede access to the receptor. This is why low affin ity li ga nd s have no di scernibl e effects at low concentrations. Even ago ni sts with relatively similar affinity but different intrinsic activity are incapable of producing linear isoboles, commonly us ed to detect DA (see Section 2.2 above), beca use the physiologica l response refl ects both affinity and intrinsic activity. Drugs or chemica ls that differ in intrinsic activity will necessarily compete at a molecular site of action and will not produ ce a linea r DA co mbined response, as demonstrated mathematically and empirically by Tallarid a (2006, 2007 ) .
In co ntradiction of these principles, DA-CAOS posits, for example, that any dose of a weak androgen receptor antagonist will diminish th e physiological activity of dihydrotestosterone by som e finite degree, irrespective of whether its affinity approaches that of a natural li ga nd . This dem onstrably fau lty premi se provides th e underlying basis for the DA-CAOS supposition that chemicals capabl e of reducing androgen levels at hi gh doses will add to the effect of weak receptor antagonists eve n at very low doses. In fact, however, multiple chemi cals given at doses incapable of affecti ng physiolog ical processes individually, by separate mec hanisms, would not be ex pected to produce a physiologica l effect in combination. A combined physiological effect would not be expected unless doses of those chemi cals were on the cusp of producing overt effects individually. In other words, fundamental pharmacological principles di ctate t hat a weak androgen rece ptor antagonist would not produce a combination effec t with an androgen synthesis inhibitor or Leydig cell toxicant unless the doses w ere sufficient to redu ce both the conce ntration of end oge nous androgen and the numbers of available receptors to levels nea r t he critical minima necessalY for su ppo rting normal physiology. The DA-CAOS theOlY fails' to recognize that the presence of myriad weak hormone receptor agonists and antagonists in the environment would fail to be DA in co mbinatio n or to ac hi eve physiol ogical significance, in part because their weak properties cancel one anothe r and in part because their low affi ni ties and intrinsic act ivi ties preclude it (Safe, 1998; Talla rid a, 2006) . Furthermore, the role of pharmacoki neti cs and how th ese phenomena may chan ge with dose and ratio of mixture constituents is often und er-appreciated in disc ussions of the joint t ox icity of chem icals. This is important because phannaco kin eti c alterations underlie th e majority of documented interactions betwee n chemica ls (Kri shnan and Brodeur, 1994) and the dose-dependence of many toxicity mechanisms, even for single chemicals (S li kker et aI., 2004) . Obviously, the potential for concomitant administration to affect the absorp tion, distribution, m etabolis m and excret ion of chemicals in mixt ures increases with dose and the number of chemical constituents as the und erlying processes that co ntrol eac h reach the limits of their capacity. Such influences would be of greatest consequence for highly potent compounds. Wi thout understandin g how pharmacoki netic processes change with dose and ratio of constituents, it is impossible to reliably extrapolate co mbination models across different dose ra nges and chemical ratios. Neith er the mi xture studi es of potential antiandrogens (Table 2 ) nor the NRC re port (NRC, 2008) considered these issues.
Testing predictions of the DA -CAOS co ncept
Despite the uncertainti es inherent in the publis hed mi xtures studi es and the unn ecessary conservatism introduced into the risk assessment by ass uming DA at all chemical concentrations, it is important to consider whether the logical extensions of the DA-CAOS theOlY are non ethel ess concordant with human clinical and e pidemiological experience. To test this concordance, an attempt was m ade to reconcile the incid ence ofTDS in humans with application of the DA-CAOS concept to the full suite of chemicals alleged to have anti-androgen ic potenti al. As well, the DES doseresponse for mal e reproductive tract malfor mations was cons idered according to the DA-CAOS concept in lig ht of extant in fo rmation regarding other environmental expos ures durin g the period when DES was administered to pregnant women.
1. In cidence of TDS and cumulative exposure to anti-androgens
The published ri sk assessment based on the DA-CAOS concept ((ortenl<amp and Faust, 2010) concludes that ..... th e cumulative risks from anti-androgen exposures exceed acceptable levels for people on the upper end of exposure levels," i.e., the upp er 95% co nfid ence interva l of human expos ures to only 15 anti-androgenic chemicals. This co nclusion impli es that pregnant women and their fetuses are at an un acce ptably hi gh ri sk for an ti-androgeni c effec ts, and specifica lly, that approximately 5% of male fetuses are at risk for development of TDS. The auth ors also claim that 8% of all know n chemica ls are li kely to possess anti-androgenic potential, including thousands of chemicals on the market in the European Union (Kortenkamp and Faust, 2010) . Presumably, similar exposures occur in other industrialized nations. Logically extending the DA-CAOS theory would thus project that the percentage of human fetuses at risk for the development of TDS is actually much higher than 5% if expos ure to all chemicals with anti-androgenic potential w ere included. Given the author's co ntention that thousands of chemi cals marketed in Europe may have anti-androgenic potential, their published ri sk assessment on 15 anti-androgens co nsid ered only 1 % or fewer of th e releva nt chemicals. If one further considers that in utero ex pos ures to over-th e-counter analgesics have also been linked to similar male reproductive tract disorders in rats and humans (Kristensen et al., 2011) , th e projected percentage of affected fetuses should approach 100%, depe nding on exposure levels for the various putative anti -androgens.
However, the actual incidence of TDS co uld not be nearly so hi gh, as the in cidence of hypospadias and cryptorchidi sm have been estimated at between 0.2-1 % and 2-9% respectively (Top pari et aI. , 2010). Even without co nsidering the DA-CAOS theOlY, some clinicians have qu estioned th e etiol ogic rol e of industri al chemi ca ls in TDS (Thorup et aI. , 2010) , asserting that the epidemiologi cal data do not support such a relationship. Their in-depth ana lysis of the in ci dence and biology of these male reproductive tract abnormalities argues against the existence of a 'syndrome' of effects caused by a common etiologic agent(s), instead pointing to a complex array of clinical diagnostic, genetic, and other factors that may be individually involved in the apparent increased incidence of hypospadias, clyptorchidism, testicular cancer and other malformations (Thorup et aI. , 2010) . For example, an analysis by Fisc h et al. (2001 ) revealed that hypospadias was significantly associated with increasing maternal age as a consequence of more women who delay childbearing until their mid-30s. It is also worth noting that Sharpe (2003) , who was initially one of the principle proponents of the TDS hypothesis as a consequence of in utero/ neonatal exposure to a variety of weakly estrogenic compounds from the environment, offered the following reassessment: "What is reasonably clear is that all of the identified "environmental estrogens" possess weak or velY weak intrinsic estrogenic activity when measured by conventiona l in vitro and in vivo assays for estrogenicity .. , By comparison with the potency of DES, for which there [are J both human and rodent data on incidence of male reproductive developmental disorders following in utero exposure (or neonatal exposure in rodents), it seems unlikely that any of the identified environmental compounds could induce either C1yptorchidism, hypospadias or testis germ cell cancer and only a tiny possibility that such compounds could affect sperm counts/sperm production . . . . Based on estrogenic potency, human exposure to the most potent environmental estrogens would need to be at least 1000-fold higher than this level for adverse effect s relevant to the human male to be induced, and such levels of exposure are remote."
Cumulative exposure to anti-androgens and clinical threshold for DES
Because normal deve lopment of the male reproductive tract is dependent on the androgen/estrogen ratio, the DA-CAOS theory predicts that cumulative exposure to environmental estrogens, anti-androgens, and other chemicals that can produce TDS-like abnormalities will increase its incidence in a DA manner. Although great concern has been generated over current cumulative exposures to anti-androgenic chemicals, it is generally acknowledged that human exposures to a wide array of chemicals capable of affecting the developing male reproductive tract -both antiandrogenic and estrogenic -have decreased since the period during which diethy lstilbestrol (DES) was administered to pregnant women and its eventual removal from the market. in part for its TDS-like effects induced in utero [see Section 2.5.1 for a detailed di scuss ion). Polychlorinated biphenyls (PCBs) (Andri c et aI., 2000a,b ; Gray et aI., 1999) chlorinated pesticides (Fern andez et aI., 2007 ; Kel ce et aI., 1995) , and 2,3,7,8-tetrachloro-p-dioxin (TCDD) (Gray et aI., 1995 (Gray et aI., , 1997 . Given that use of high-dose over-the-counter analgesics, which have also been associated with male reproductive tract malformations (Kri stense n et aI., 2011), was also common during the era wh en DES was given, it seems highly probable that exposures to chemicals capable of producing TDS-like effects were substantial during the DES episode, and most certainly hi gher than today.
If, as th e DA-CAOS risk assessment predicts, a significant proportion of male fetuses experience anti-androgenic effects today, at least as high a proportion would likely have experienced such effec ts during the era of DES use in pregnancy. Assuming the DA-CAOS theory, it would follow that any dose of DES should have produced an observable increase in the incidence of TDS-Iike effects above the predicted observable background of chemicalinduced male reproductive tract malformations. In contrast, no clear increase was observed in the incidence of TDS-like effects 321 with the lower-dose regimens of DES (Dietrich, 2010 ; Go ld en et aI. , 1998).
Human versus rat sensitivity
One reason the hazard index-based DA-CAOS risk assessment (Kortenkamp and Faust, 2010 ) is irreconcilable with human clinical and epidemiological evidence is it employed reference doses (RIDs) that were developed without considering relevant data and physiological knowledge concerning species-specific sensitivity for chemical effects on the male reproductive tract (Cook et aI., 1999 ; Hallmark et aI., 2007; Scott et aI., 2009 ). The derived RIDs incorporate uncertainty factors of 200-500 (Kortenkamp and Faust, 2010) , consistent with an assumption that adverse effects on the developing male reproductive tract may be observed in humans at doses 200-500-fold lower than doses required to elicit such effects in rats. In the absence of relevant human data, such procedures are considered appropriate for extrapolating rodent toxicity data to humans. However, direct human data are available for many human pharmaceuticals, including drugs with antiandrogenic and/or TDS-like effects. The assumptions made in the risk assessment were thus tested against such human data. Data were evaluated by comparing human versus rat data from (a) in utero exposures to DES, a chemical that produces TDS-Iike malformations of rodent and human reproductive tracts by inducing androgen deficiency secondalY to functional disruption of Leydig and Sertoli cells, and (b) human versus rat administration of finasteride, an anti-androgen that produces androgen defici ency by inhibiting conversion of testosterone to its active form, dihydrotestosterone.
Human versus rat -DES
To test the premise that chemicals affect the developing male reproductive tract of humans at doses 200-500 lower than in rats, human clinical data on gestational exposure to DES were compared with data from concordant exposures in the rat. Although DES is a potent estrogen agonist that interferes with Sertoli and Leydig cell function in rodents, some of its adverse effects on the male reproductive tract are complex, e.g., may involve both estrogen (Couse and Korach, 2004) and androgen pathways (Goyal et aI., 2009 ; Riva s et aI. , 2003 ) , and exhibit both sim ilarities and differen ces compared to pure estrogens such as estradiol 1713 (Adachi et aI., 2004; Khan et aI., 1998; Lassurguere et aI., 2003; Wari ta et aI., 2010) . In addition to reducing activity of the steroidogenic acute regulatory protein (StAR) and other effects similar to those produced by some phthalates in rats (Guyo t et aI., 2004; Howdes he ll et aI., 2008a; Ikeda et aI., 2008 ), treatment or neonatal rats with testosterone or dihydrotestosterone prevents most effects of DES on the developing male reproductive tract (Rivas et aI., 2003; Goya l et aI. , 2009) , providing evidence that androgen deficiency or alteration of the androgen-estrogen balance is involved in DES action. Loss of Leydig cell function, also proposed for phthalate esters (David, 2006; Howdes hell et a I. , 2007) , is one of many anti -androg~nic modes of action that can result in androgen deficiency and is encompassed by the DA-CAOS concept. Thus, the action of phthalate esters on fetal Leydig and Sertoli cells appears to be more similar to DES than to the other anti-androgens assessed in the mixtures studies analyzed here (Ta ble 2 ).
Beginning in th e 1940s, DES was widely prescribed to some 5 million pregnant women under the mistaken assumption that it prevented miscarriage. The discovery that gestational exposure to DES induced a low incidence of clear cell vaginal adenocarinoma in daughters and a low incidence of male reproductive abnormalities in sons led to its removal from the market in 1972. Its effects on sons exposed in utero, including epididymal cysts, IJ g/kg/day DES Fig.4 . DES potency compa ri son for mal e reproductive t ract parameters. Human clinica l data (ovals) Rat experi mental data (triangles). Asterisks (*) denote no-effect doses. Plus (+) denotes in utero administration. Pregnant women were assumed to weigh 70 kg. Where doses to rats w ere not reported per body weight, body weight data from Klinger et al. (1996) or Pullen (1976) were used to ca lcul ate a pproximate administered doses. mi crophallus, cryptorchidism, testicul ar hypoplasia, reduced sperm counts, and increased incidence of abnormal sperm (Di etrich, 2010; Golden et aI., \ 998) have made DES the prototype for chemical-induced TDS in humans, showing nearly identical effects in rats and humans (Toppari et aI., 2010) . Beca use no clinical trial had been conducted with DES to verify efficacy and optimize dosage, the total DES dose administered varied among clinics by more than an order of magnitude. Mal e reproductive tract abnormalities were significantly inc reased only among offspring of mothers enroll ed in clinics that employed the hi gher dose regimens, i.e., administration of 12-1 8 g DES during pregnancy (Di etrich. 2010; Go lden et aI., 1998 ) , or approximately 844-1266 J.lg/ kg/day, assuming a body weight of 70 kg per pregnant woman. In contrast, no clea r increase in incidence of male reproductive tract effec ts has been observed in offspring of mothers given lower dose regimens of DES, i.e., administration of 1.4 g DES during pregnancy (Di etrich, 2010; Go lden et aI., 1998; Leary et aI., 1984) , equivalent to 71 J.lg/kg/day for the · first two weeks and 99 J.lg/kg/day during th e entire pregnancy. Plotting these dos es aga inst data from studi es conducted in rats (Fi g. 4 ) demonstrates that effects on the developing male reproductive tract are observable in rats at DES doses approximately 1-2 orders of magnitude lower than those required to produce simila r effects in humans. Th e data also indicate that the male rat reproductive tract is similarly sensitive across fetal, neonatal and adult life stages. In a detail ed analysis of species differences with respect to in utero DES-induced male reproductive tract anomalies, Hoga n et al. (1987) compared the relative potency ratios for these effec ts in the mouse (the prototypical animal model for DES-induced reproductive tract effects) and humans. Depend ing on various assu mptions, effects in humans occurred at doses from 1-2 orders of magnitude greate r, to approximately equal those at which effects occurred in mice. Thus, both rat and mouse data chall enge the seemingly arbitrary assumption that ma le reproductive tract ma lformation s occur in humans at DES do ses 200-S 00-fold less than req uired to produce effects in rodents (Kortenkamp and Faust, 2010) . Although there could be speculation on mechanistic grounds as to why humans might be less sensitive than rodents to effects of DES but not to effec ts of other chemicals with potential anti-androgenic properties, such speculation would presumably be irrelevant within the context of the DA-CAOS concept wherein mechanisti c similarity is not a criterion for pred icting combination effects. Consequently, the co mparison of human versus rat se nsitivity to the effects of DES on the devel oping male reproductive tract appears to be relevant for the risk assessment of anti-androgens within the DA-CAOS concept, es pecially for phthalate esters. Thi s comparison would seem to be an obligate exercise for using rat data to conduct a human health ri sk assessment, es pecially when the data are publicly ava ilable.
Hllman verSllS rat -jlnasteride
To further test the assumption that anti-androge nic chemi cals affect the human male reproductive tract at doses lowe r than in the rat, data were compared for effects of finasteride, a human pharmaceutical presc ribed for its anti-androgenic e ffects in the treatment of beni gn pros tat ic hypertrophy (Go rml ey et a I., 1990). Finasteride was among the mixture of anti-androgens reported to synergistically induce reproductive tract abnormalities in ma le rats following in utero administration (Chri stiansen et aI., 2009 ). Finasteride is a specific inhibitor of Sa red uctase, the enzyme res ponsible for conversion of testosterone to dihydrotestosterone, the active androgen receptor li ga nd and agonist in humans and rodents. The inhibition of Sa reductase by finasteride is not mediated through DHT binding to the androgen receptor, thus mimicking hereditary Sa reductase defici ency where individuals with this deficie ncy present with poor prostatic growth (G orml ey, 1992; Gorm ley et aI., 1990) . Finasteride has been shown to significa ntly reduce prostate s ize in humans and in seve ral animal models. Both testosterone and dihydrotestosterone (DHT) are criti cal fo r normal male reproductive development. DHT is required for no rma l development of th e ex ternal ge nitalia and prostate (Bowman et aI. , 2003 ) .
Significant variability attends es tab lishing a threshold for percent redu ction in DHT in humans, as seen in Fig. 5 , The lowest dose Table 3 ).
at which a reduction of DHT was seen in men was 0.0006 mg/kg and ranged from 10% after one-day exposure to 50-60% after 14-day exposure (Gormley et aI., 1990) . In this study, a statisticall y significant pe rcent reduction (approximately 40%) in DHT occurred in the baseline va lues for two treatment groups, further indicati ng the sign ificant variabi li ty if t hi s effect. The maximum suppression of DHT in serum is approximately 70% and occurs at doses > 0.007 mg/kg (Steiner, 1996) . The plateau in suppression of serum DHT is shown out to 1 mg/kg in Fig. 5 . Maximum suppression of DHT in the prostate is 85-90%. Finasteride has much greater affinity for the type 2 50! reductase isozyme than for the type 1, hence, the remaining DHT in the serum and prostate gland is likely to be the result of type 1 50! reductase (Bartsc h et al" 2002) . Very little data were found to establish a thresho ld for the reduction of serum DHT in the rat. A thres hold for the effect of DHT on the prostate ha s been demonstrated in rats, however the thresho ld is only apparent when the animals have been castrated, resu lting in very low intra-prostatic testosterone and DHT levels (Ba rtsch et aI., 2002) . Thresholds for effects on male reprodu ctive development in the rat using both standard developmental toxicity studies and the Hershberger assay are also shown in Fi g. 5. Finasteride ca uses a decrease in anogenital di sta nce in male offspring. The threshold for reversi ble decreased anogenital di stance is 0.003 mg/kg (Clark et aI., 1990) but is somewhat higher for irreversib le decreased anogenital distance as determined by its presence at post-natal day 90 (Bowman et aI. , 2003 ) . Fig. 5 shows that the threshold for a clinically effective decrease (Fi g. 5J) in circulating dihydrotestosterone in men occurs at approximately the same finasteride dose as produces a reduction in rat anogenital distance in the Hershberger assay (Fi g. 51) . Thres holds for other effects in rats are observed at significantly higher doses, but still lower than the recommended clinical dose for treatment of benign prostatic hypertrophy in men (Fi g. 5S). Taken together, the above data strongly suggest that irrespective of the high variability in both huma n and rat data, effects of a potent anti-androgen, finasteride, occur in human males at doses no lower than, and most li ke ly considerably hi ghe r than are required to produce effects in the rat.
The Human-Relevant Potency-Threshold (HRPf)
As a conservative screening level assessment, the DA-CAOS concept may have some utility since it is reasonably simple to perform, requires only rudimentary dose-response information and dema nds virtuall y no understanding of mode of action, pharmacokinetics, or stru cture activity relationships. However, as demonstrated above, the DA-CAOS theOlY suffers an inordinate degree of uncertainty as evidenced by limitations in the studies on which it is based, contradicts fundamental tenets of pharmacology, and wou ld predict outcomes incongruous with human clinical and epidemio logical observations. The published risk assessment based on DA-CAOS magnifies those uncertainties with unnecessary conservatism regarding doses at which effects occur in humans versus rats. Thus, for any group of chemicals that warrant further analysis -for which concern might remain after conducting a DA-CAOS screening assessment -a better approach is needed that is well grounded in fundamenta l pha rmacologica l principles, can be reconci led with human clinical data, and is consistent with clinical epidemiological experience.
Consequently, an improved ri sk assessment and prediction strategy is proposed that melds those features of the DA-CAOS co ncept that are tenable with requ irements of the TEQ co ncept that are necessary to conform with fundamental pharmacological principles and to be compatible with the observed clinical and epidemiological data. The proposed approach, referred to as the Human Re leva nt Potency Threshold (HRPT) approach, proposes that DA be assumed for chemicals that can affect a common adverse outcome, but only at doses close to the lower limit of the observable effect range. It also proposes that DA be applied to chemicals that meet the TEQ requirements for receptor-or enzyme-mediated adverse effects and whose potency approaches that of an endogenous li ga nd or human pharmaceutical. In both cases, the observable effect dose or the potency of a natural liga nd or human pharmaceutical should be based on human data whenever ava il ab le. Below these 'thresho lds' in either dose or potency (affinity/intrinsic activity), IA wou ld be used for cumulative risk assessment of chemicals to which humans are exposed; i.e., Table 3 Human clinical data (ovals) rat experimental data (triangles). Blue points indicate % reduction in DHT. 
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The HRPT a pproach accommodates both th e DA-CAOS conce pt. where tenabl e. and the w ell-established TEQ conce pt. but improves upon each by providing a m ea ns for ca librating the assumption of DA with human data. The approach is broadly appli cabl e whenever human data are available to support estimation of human-rel evant thres holds. A conce ptual diagram of the HRPT approach is presented in Fig. 6 . which can be clearly contrasted with the DA-CAOS concept as depi cted in Fig. 2b . Althou gh the HRPT approach will not be possibl e for all chemicals du e to lack of human data, th e HRPT approach will be feasible in many cases. including any adverse outcome or interm edi ate step in th e production of an adverse outcome that can be produced by a human pharmaceuti cal agent. For the pharmaceuti cal agents consid ered in thi s manuscript. DES and fina sterid e. clinical and rodent data were readily avail a bl e in th e published literature.
Th e ste ps necessary for applying th e HRPT approach in cumulative (combined exposures) risk assessment include : 1, Definin g th e common adverse outcome or target organ effect upon which the cumulative effec t from a g roup of chemi ca ls is to be based . In most instances, thi s will be defin ed based on animal toxicology studi es. but care should be taken to avoid effects th at are arguably s peci es specific and of qu es tionabl e relevance to humans. It is important that th e effect is defin ed (Table 2) have been perform ed relative to th e dose-response curves fo r obselvable effect s (Q) . Th e HRPT approach proposes that DA be assumed fo r chemi cals that can affect a common adverse outcome, but only at doses (5 1) that approach the lower limit of the obselva ble effect ra nge (Q), as depi cted in the top pa nel. For cumulative ri sk assessments, IA would be used to combine chemica ls to w hich humans are exposed that fa ll below these 'th res holds' (S2, boltom panel) in either dose or potency.
specifically and that constellations of effects be avoid ed unl ess cl ea rly and definitively related by physiological and m echanistic understanding.
2. Identifying the chemicals known to produce the common adverse outcome in the test species and determining whether data indicate DA combined effects of those chemicals. If demonstrable, identify the lowest concentrations in mixtures at which DA occurs. 3 . Defining, if possible, the modes of action that can lead to the adverse outcome in the test species. 4. Identifying chemicals, including drugs, known to produce the adverse outcome in humans, including among these, chemicals or drugs known to operate by relevant modes of action that can produce th e adverse outcome. 5. Identifying chemicals for which the TEQ concept is justified based on satisfying TEQ requirements (see Table 1 ). 6. Gathering and comparing dose-response data for the chemicals an d drugs of interest in humans and the test species, whether based on end-organ toxic effects or intermediate, obligate steps in the production of toxicity. An example of the former is the comparison of the DES doses at which male reproductive tract malformations occur in humans versus rats; the latter, the comparisons based on doses of finasteride. Fortunately, because data providing direct dose sensitivity comparisons for frank adverse effects are rare, such as those for DES, comparisons based on measures of pharmacological effects will often be required . 7. Based on the comparisons of human versus test species sensitivity, potency differences between chemicals, and concentrations at which DA adverse effects are demonstrable in test species, estimating the potency differential between species, and thus the potency threshold at which DA would be a conservative but tenable assumption for humans. Defining these potency thresholds is required for TEQ-compliant chemicals as well as for broader groups based only on common adverse outcome or intermediate steps in toxicity.
Application of the HRPT approach to potential antiandrogens
The first three steps for applying the HRPT approach as outlined above were assumed from the NRC report (NRC, 2008) and the mixtures studies cond ucted on chemicals with potential antiandrogenic properties (see Tabl e 2 ).
Step 4 involved identification of DES as a chemical known to produce the common adverse outcome in humans, and identification of finasteride, a chemical included in the one of the subject mixtures studies (Chris t ia nsen e t aI. , 2009) which has a defined mode of action and clearly measurable clinical endpoint in humans. Chemicals that are potent inhibitors of S-alpha reductase, androgen receptor antagonists, and phthalate esters that interrupt Leydig and Sertoli cell development may be candidates for three separate TEQ gro upings (Step 5).
Step 6 has been outlined previously in this paper and is summarized in Figs. 4 a nd 5.
Step 7 is described below using phthalate esters and finasteride as examples to illustrate how the HRPT approac h is applied based on dose level and potency respectively.
For the broad groupi ng of chem icals with potential anti-androgenic properties, an HRPT should be set on dose level rather than potency because these chemicals do not satisfy TEQ criteria for application of DA across untested dose ranges. Based on the ana lysis outlined in steps 1 through 6 and the ana lysis presented in Section 2.4.1 and Fi g. 4, a proposed dose-based HRPT for the broad grouping of phthalate este rs and other che micals with potential anti-androgenic properties can be conservatively set at doses 5-fold below rat LOAELs/NOAELs for CAOS on the developing male reproductive tract. Thus, for example, the HRPT approach would app ly DA to combi ned human phthalate exposures that are within a factor of S-fold lower (i.e., 20%) than rat LOAELs/NOAELs for effects on the male reproductive tract, but would apply IA to lower 325 expos ure levels, i.e., for cumu lative risk assessment at current levels of human exposure to phthalates. Since the DES dose required for human in utero effects is approximately 1-2 orders of magnitude greater than required for rats (Fig. 4) , an HRTP above the rat LOAELs/NOAELs may be justifiable. Thus, the proposed dose-based HRPT of S-fold below the rat LOAELs/NOAELs for assuming DA in a cumu lative risk assessment is a conservative estimate for TDS-like effects on the developing male reproductive tract of humans, and likely provides at least an additional order of magnitude conservatism. Although the DA-CAOS co ncept does not require a mechanistic rationale for estimating combined effects, the fact that both phthalates and DES produce effects on the developing male reproductive tract secondary to inhibition ofLeydig and Sertoli cell function provides relatively high confidence that a dose-based HRPT of S-fold below the rat NOAEL is adequately protective of human health.
Over the past decade, a number of epidemiology studies have appeared in the scientific literature that compared urinary concentrations of phthalate metabolites and developmental effects in infants, including anti-androgenic effects (e.g., Clyptorchidism, anogenital distance). Those studies have a number of features in common : a proposed hypothesis based on the results of animal studies, limited populations, limited number of biomarker samples during pregnancy, and limited concurrence with animal data. Although virtually all of the stud ies report one or more statistica lly significant associations, none offer a basis for testing the HRPT approach on the potential for anti-androgenic effects in infants exposed to individual or multiple phthalates. Causal interpretation of the epidem iological findings is problematic due to severa l limiting factors, which are ofte n well described by the investigators. In addition, there is a considerable amount of inconsistency among the human studies and between the animal and human stud ies.
Human versus rat comparisons for the potency of finasteride suggest a conservative potency-based HRPT of 1 order of magnitude below the potency of finasteride for effects on the rat male reproductive tract from androgen deficiency via inhibition of S-alpha-reductase. This potency-based HRPT would be applied to chemicals meeting TEQ criteria for similarity of mode of action and structure-activity parameters with finasteride, and provides approximately an order of magnitude conservatism based on data indicating that humans have simi lar se nsitivity as rats to effects of fina s teride, as explained above in Section 2.4.2 and illustrated in Fig. 5 . This potency-based HRPT would trigger the assumption of DA for all chemicals meeting TEQ criteria whose potency for inhibition of S-alpha reductase is within one order of magnitude that of finasteride. Chemicals with lower potency would be assessed by lA, or by DA using an HRPT set on dose, in this instance, at doses within S-fold below their individual NOAELs/LOAELs for CAOS on the developing male reproductive tract. Although we have not derived potency-based HRPTs s pecifically for androgen recepto r a ntago nists or for inhibitors of particular e nzymes in the steroidogen ic pathway, these would be derived as was done for finasteride if cumulative assessments are desired for exposure to groups of chemicals that act specifically by these mod es of action.
Applying the HRPT approach to the risk assessment for 15 antiandrogens results in an estimate of risk for phthalates 2 or more orders of magnitude lower than concluded in the published assessment (Kortenka mp and Fa ust, 2010) . This is due to the fact that a conservative HRPT of S-fold below the rat NOAEL precludes application of DA to lower human exposures, whereas Korte nka mp a nd Faus t (2010) assumed DA for all dos es and ratios based on human Rffis 200-S00-fold lower than rat NOAELs. In contrast, use of the more biologically plausible HRPT approach leads to a co nclusion that under current exposure conditions, phthalates s hould not be assessed by DA, and that few, if any of the other chemicals included in the published risk assessment (Kortenkamp and Fa us t. 2010) should be assessed by DA at curre nt exposure levels. Instead, IA should be applied to those chemi cals.
Conclusions
Limitations in the study designs fo r mixtures of rod ent antiandroge ns (Tab le2), albeit imposed by practical necess ity for studies in live animals, impart an undefined level of uncertainty to th e extrapolation of experim ental results beyond th e doses and rati os tested. Additi onal un certainty is introduced by the us e of scored endpoints and the way these scores were combined for some analyses. A statistical analysis of precision usin g published data from th e mixtures studi es in qu estion indicates that the model predictions may vary as mu ch as 2-fo ld for th e dose ratio and concentrations of chemi cal s tes ted. This variance would expand with extrapolation to untested ratios and doses. Extrapolation to lower doses is totall y depend ent on the model employed and beca us e no data exist to support the extrapolation, this could dramatically in crease variability and lead to erroneous conclusions. These fa ctors reduce the confid ence that can be placed in the conclusion that mixtures of antiandrogens are DA, even wi t hin the dose ranges evaluated, but even moreso at untes ted concentrations and ratios. No objective information allows one to conclude that DA is more accurate than IA at relevant human exposure levels. Given the qu es tions rai sed here (Section 2.2) and the fa ct t hat th e Rid er et al. (2008) and Metzdo rff et al. (2007) data, taken together, indicate that DA as well as IA predi ct a vari ety of relevant responses in th e developing male reproductive tract of rats, it is uncl ear if not unscientific to assume DA by default based on a preference for conservati sm, as claimed (I<or-tenkamp and Fa ust, 2010) . Since ri sk manage ment decisions often involve choosing between various options, it is impossible to make those decisions in a precautiona ry mod e wi thout understanding the underlying accuracy of scientific assessments. Therefore , the preference of models used to scientifi ca lly assess human health risks would be best based on data rather than on pres umptions abou t wha t constitutes a precautionary decision.
The DA-CAOS theory is in consistent with established pharmacological principl es that relate affinity, intrinsic activity, and efficacy to relative potency es timati on, and overlooks potential dose-depend ent changes in phannacokin eti c intera ctions. Logica l predicti ons of the DA-CAOS co nce pt are also in co nsistent wi th available clinical and epidemiological informati on. Th e incidence of TDS in humans, consid ered by so me to be co nsistent with ph t hal ate syndrome in rats, is quite low, whereas applyin g th e DA-CAOS theOlY to all potenti al anti -androge ni c drugs and chemicals would predict an epidemi c of th e syndrome affecting nearl y the entire human popUlation. Th e strong suggestion of a clinical thres hold for DES-induced male reproductive tract malform ati ons is inconsistent with the ass umption of DA-CAOS, give n the fa ct that human expos ure to many anti -and roge ni c drugs and chemical s was significant during the DES episode. If combined exposures to chemi cals that can affect a CAOS truly operate by DA irrespecti ve of th eir potencies and concentra tion s, it is diffi cult to imagin e how living organisms could survive in a world composed of hundreds of th ousands of chemi cals, all of which produ ce ove rt toxicity at so me level of ex pos ure. Indeed, t he DA-CAOS th eo ry contravenes well -established principles of pharm aco logica l and toxicologica l action evidenced by mechani sti c and clini cal da ta derived from human pharmace utical experi ence.
Comparison of published data fo r human and rat male reproductive tract sens itivities to DES and fi nasteride reveals that relying on rat data whi le ignoring th e relative sensitivity of the human fetus has introduced consid erable but unn ecessa ry un certainty and co nservati sm to the published human health ri sk assessments for anti-a ndroge ns (I<ortenkamp and Faust, 2010 ; Benson, 2009) . The magnitude of thi s unnecessary conse rvatism is at leas t 2 orders of mag nitud e, and perh aps as mu c h as 4 orders of magnitude. Taken together, th e un certainti es and conse rvatism introduced by applying DA to all anti-androgens at a ll doses, irrespective of mechani sm, and ignoring human versus rat sensitivity rend er scientific conclusions based on the mi xture studi es at iss ue te nu ous and regulatOlY decisions based on the risk assessment utili zing such studi es arbitra ry.
Th e DA-CAOS recommendation and the risk assessment based upon it are radical departures from past EPA practice regarding similarity criteria for applying dose addition (Tab le 1 ) (Borgert et aI., 2004) . Furthermore, this approach appears to ig no re the entire logic of t he TEQ requirements, which w ere deve loped as inclusion cri teria for app lying DA in cumulative risk ass essments, i.e., to increase th e reli abi lity of extrapolating the DA ass umption beyond empi rical data. Nonetheless, beca use sophisticated pha rmacological and toxico logical knowledge is not required for its application, the DA-CAOS concept could be ration ally appli ed, but only as a coarse screening level assess ment. This is consistent with the hi storical use of hazard-index based approaches, which are used in screenin g-level baseline risk assess ments to project acceptable clea nup criteri a for hazardous waste sites.
If a DA-CAOS-type assessment sugges ts that human ex posure to some groups of chemicals may exceed its conservative parameters, a more biologically based method of assessing actual risk is warra nted. We have proposed such a method -the HRPT app roac h -to fulfill this need. The HRPT approach builds upon tenab le ass umptions of th e DA-CAOS app roach and t he more biologically based TEQ approach used for decades by EPA and other regulatory bodi es, but offers a means of improving th e accuracy and reliabi li ty of the ri sk assessment by incorporating human data into the potency and combined-effect ana lysis. Th e HRPT approach is widely a pplicable and is feasible for any type of effect tha t is produced by groups of chemicals for which direct human data are avail able. Given the wide array of pharmacological modalities by whi ch human pharmaceutical s act, suffici ent data are available for app lying th e HRPT approach broadly in toxi cological ri sk assessment.
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